Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bristol-Myers Squibb Co, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Bristol-Myers Squibb Co, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Bristol-Myers Squibb Co, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Bristol-Myers Squibb Co, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Bristol-Myers Squibb Co, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Bristol-Myers Squibb Co, Medical Equipment, Deal Details 12
Venture Financing 12
Grail Raises USD914 Million in First Tranche of Series B Financing 12
Partnerships 15
Guardant Health Enters into Agreement with Bristol-Myers 15
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 16
HTG Molecular Diagnostics Enters into Research Agreement with Bristol-Myers Squibb 17
SomaLogic Enters into Agreement with Bristol-Myers Squibb 18
Leica Biosystems Enters into Co-Development Agreement with Bristol-Myers Squibb 19
InCell Enters Into Co-Development Agreement With Bristol-Myers Squibb 20
Adaptive Biotech Enters Into Co-Development Agreement With Bristol-Myers Squibb 21
Opko Health Expands Co-Development Agreement With Bristol-Myers Squibb For Alzheimer’s Biomarkers 22
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 23
Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 24
Bristol-Myers Squibb Enters Into Co-Development Agreement With Meso Scale 25
Dako Enters Into Co-Development Agreement With Bristol-Myers 26
Bristol-Myers Squibb, Saladax Biomedical And Ortho-Clinical Diagnostics Expand Co-Development Agreement 27
Opko Health Enters Into An Agreement With Bristol-Myers Squibb 28
Equity Offering 29
GeneCentric Diagnostics Raises Funds through Equity Financing 29
Panmira Pharmaceuticals Spin Out from Amira Pharmaceuticals 30
Debt Offering 31
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 31
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 33
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 35
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 37
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 39
Acquisition 41
Bristol-Myers Rumored To Acquire Biogen Idec 41
Bristol-Myers Squibb Co – Key Competitors 42
Bristol-Myers Squibb Co – Key Employees 43
Bristol-Myers Squibb Co – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 51
Recent Developments 52
Strategy And Business Planning 52
Nov 01, 2017: Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York 52
Dec 13, 2016: Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint 53
May 17, 2016: Bristol-Myers Squibb Opens Expanded Biologics Facility 54
Mar 16, 2016: Allied-Bristol Life Sciences Launches ißeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway 55
Financial Announcements 56
Oct 26, 2017: Bristol-Myers Squibb Reports Third Quarter Financial Results 56
Jul 27, 2017: Bristol-Myers Squibb Reports Second Quarter Financial Results 58
Apr 27, 2017: Bristol-Myers Squibb Reports First Quarter Financial Results 61
Jan 26, 2017: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results 64
Oct 27, 2016: Bristol-Myers Squibb Reports Third Quarter Financial Results 67
Jul 28, 2016: Bristol-Myers Squibb Reports Second Quarter Financial Results 71
Jan 28, 2016: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results 74
Corporate Communications 77
Oct 09, 2017: Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine 77
Sep 13, 2017: Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors 78
Apr 10, 2017: Bristol-Myers Squibb Earns ENERGY STAR Partner of the Year Award for Third Consecutive Year 79
Mar 08, 2017: Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer 80
Feb 21, 2017: Bristol-Myers Squibb Appoints Three New Independent Directors 82
Dec 21, 2016: Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors 83
Jul 25, 2016: Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head 84
Jun 20, 2016: Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer 85
Mar 03, 2016: Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors 86
Feb 03, 2016: Bonnie J. Addario Lung Cancer Foundation Honors Bristol-Myers Squibb for Improving and Advancing Breakthrough Treatments for Lung Cancer 87
Product News 88
Sep 28, 2016: Intensity Modulated Radiation Therapy Associated with Reduction in Patient Reported Xerostomia in Head and Neck Cancer Patients 88
Jun 07, 2016: NRG RTOG 0617 Shows Survival Correlation for Low versus High Enrolling Institutions for Patients with LA-NSCLC 89
May 05, 2016: Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released 90
Apr 14, 2016: Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies 91
Other Significant Developments 92
Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 92
Jun 01, 2016: Bristol-Myers Squibb Executive to Discuss New Data-Driven Approach to Driving Sales Excellence at 2016 LTEN Conference 93
May 19, 2016: Inovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based Contracting Initiatives 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95
Bristol-Myers Squibb Co, Medical Equipment, Key Facts, 2016 2
Bristol-Myers Squibb Co, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Bristol-Myers Squibb Co, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Bristol-Myers Squibb Co, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Bristol-Myers Squibb Co, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Bristol-Myers Squibb Co, Deals By Market, 2011 to YTD 2017 9
Bristol-Myers Squibb Co, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Grail Raises USD914 Million in First Tranche of Series B Financing 12
Guardant Health Enters into Agreement with Bristol-Myers 15
Bristol-Myers Squibb Plans to Enter into Research Agreement with GRAIL 16
HTG Molecular Diagnostics Enters into Research Agreement with Bristol-Myers Squibb 17
SomaLogic Enters into Agreement with Bristol-Myers Squibb 18
Leica Biosystems Enters into Co-Development Agreement with Bristol-Myers Squibb 19
InCell Enters Into Co-Development Agreement With Bristol-Myers Squibb 20
Adaptive Biotech Enters Into Co-Development Agreement With Bristol-Myers Squibb 21
Opko Health Expands Co-Development Agreement With Bristol-Myers Squibb For Alzheimer's Biomarkers 22
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 23
Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb 24
Bristol-Myers Squibb Enters Into Co-Development Agreement With Meso Scale 25
Dako Enters Into Co-Development Agreement With Bristol-Myers 26
Bristol-Myers Squibb, Saladax Biomedical And Ortho-Clinical Diagnostics Expand Co-Development Agreement 27
Opko Health Enters Into An Agreement With Bristol-Myers Squibb 28
GeneCentric Diagnostics Raises Funds through Equity Financing 29
Panmira Pharmaceuticals Spin Out from Amira Pharmaceuticals 30
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 31
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 33
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 35
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 37
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 39
Bristol-Myers Rumored To Acquire Biogen Idec 41
Bristol-Myers Squibb Co, Key Competitors 42
Bristol-Myers Squibb Co, Key Employees 43
Bristol-Myers Squibb Co, Subsidiaries 45
Bristol-Myers Squibb Co, Joint Venture 51
